Sutro Biopharma Inc (NASDAQ: STRO) kicked off on Monday, down -8.64% from the previous trading day, before settling in for the closing price of $3.59. Over the past 52 weeks, STRO has traded in a range of $2.01-$6.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 38.48%. While this was happening, its average annual earnings per share was recorded -94.55%. With a float of $75.15 million, this company’s outstanding shares have now reached $81.79 million.
Let’s determine the extent of company efficiency that accounts for 302 employees.
Sutro Biopharma Inc (STRO) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Sutro Biopharma Inc is 8.13%, while institutional ownership is 65.26%. The most recent insider transaction that took place on Jan 29 ’24, was worth 60,925. In this transaction CHIEF PORT. STRAT & ALNCE OFCR of this company sold 12,185 shares at a rate of $5.00, taking the stock ownership to the 12,803 shares. Before that another transaction happened on Aug 28 ’23, when Company’s Chief Business Officer sold 15,428 for $4.71, making the entire transaction worth $72,595. This insider now owns 0 shares in total.
Sutro Biopharma Inc (STRO) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 3/31/2024, the organization reported -0.64 earnings per share (EPS), higher than consensus estimate (set at -0.73) by 0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -94.55% per share during the next fiscal year.
Sutro Biopharma Inc (NASDAQ: STRO) Trading Performance Indicators
Take a look at Sutro Biopharma Inc’s (STRO) current performance indicators. Last quarter, stock had a quick ratio of 4.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.89, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.57 in one year’s time.
Technical Analysis of Sutro Biopharma Inc (STRO)
Looking closely at Sutro Biopharma Inc (NASDAQ: STRO), its last 5-days average volume was 0.63 million, which is a drop from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 7.39%. Additionally, its Average True Range was 0.30.
During the past 100 days, Sutro Biopharma Inc’s (STRO) raw stochastic average was set at 15.68%, which indicates a significant increase from 4.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.88% in the past 14 days, which was lower than the 95.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.69, while its 200-day Moving Average is $3.84. However, in the short run, Sutro Biopharma Inc’s stock first resistance to watch stands at $3.37. Second resistance stands at $3.46. The third major resistance level sits at $3.54. If the price goes on to break the first support level at $3.21, it is likely to go to the next support level at $3.13. Now, if the price goes above the second support level, the third support stands at $3.04.
Sutro Biopharma Inc (NASDAQ: STRO) Key Stats
The company with the Market Capitalisation of 268.27 million has total of 81,794K Shares Outstanding. Its annual sales at the moment are 153,730 K in contrast with the sum of -106,790 K annual income. Company’s last quarter sales were recorded 13,010 K and last quarter income was -58,210 K.
